USANA Health Sciences (NYSE:USNA) Sets New 52-Week Low – Should You Sell?

USANA Health Sciences, Inc. (NYSE:USNA) shares reached a new 52-week low on Tuesday . The company traded as low as $34.59 and last traded at $34.86, with a volume of 11798 shares. The stock had previously closed at $35.05.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. DA Davidson dropped their price target on USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating for the company in a research report on Wednesday. StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 24th.

USANA Health Sciences Stock Performance

The firm’s 50 day moving average price is $37.98 and its two-hundred day moving average price is $42.55. The firm has a market cap of $696.85 million, a PE ratio of 12.93, a PEG ratio of 1.15 and a beta of 0.89.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.07. USANA Health Sciences had a return on equity of 10.80% and a net margin of 6.30%. The business had revenue of $200.22 million during the quarter, compared to analysts’ expectations of $208.45 million. During the same period in the prior year, the business posted $0.59 EPS. On average, analysts forecast that USANA Health Sciences, Inc. will post 2.5 earnings per share for the current year.

Insider Transactions at USANA Health Sciences

In related news, Director Gilbert A. Fuller sold 674 shares of USANA Health Sciences stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $39.69, for a total value of $26,751.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Gilbert A. Fuller sold 674 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total transaction of $26,751.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Turman Fleming sold 1,000 shares of USANA Health Sciences stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $44.43, for a total value of $44,430.00. Following the completion of the transaction, the director now directly owns 2,503 shares of the company’s stock, valued at approximately $111,208.29. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 7,940 shares of company stock worth $311,670. 0.33% of the stock is currently owned by insiders.

Institutional Investors Weigh In On USANA Health Sciences

Several large investors have recently added to or reduced their stakes in the business. DGS Capital Management LLC grew its stake in shares of USANA Health Sciences by 61.8% in the first quarter. DGS Capital Management LLC now owns 7,258 shares of the company’s stock worth $352,000 after acquiring an additional 2,773 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in USANA Health Sciences by 18.1% in the first quarter. BNP Paribas Financial Markets now owns 38,820 shares of the company’s stock valued at $1,883,000 after purchasing an additional 5,952 shares during the period. Pzena Investment Management LLC grew its stake in USANA Health Sciences by 3.1% during the 1st quarter. Pzena Investment Management LLC now owns 785,344 shares of the company’s stock worth $38,089,000 after purchasing an additional 23,729 shares in the last quarter. State Board of Administration of Florida Retirement System increased its holdings in USANA Health Sciences by 22.7% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 8,430 shares of the company’s stock worth $409,000 after purchasing an additional 1,560 shares during the period. Finally, BOKF NA raised its position in USANA Health Sciences by 274.5% in the 1st quarter. BOKF NA now owns 2,771 shares of the company’s stock valued at $133,000 after purchasing an additional 2,031 shares in the last quarter. 54.25% of the stock is owned by hedge funds and other institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.